Print This Issue

$2 Million from Keck Foundation for Research on Parkinson’s Disease
February 13, 2007, Volume 53, No. 22

Penn has received a $2 million grant from the W.M. Keck Foundation of Los Angeles for a pioneering study on the genomics of Parkinson’s disease. The Keck Foundation’s program supports basic biomedical research and the development of pioneering new technologies.

The grant will permit the development of technology to study the basic cell biology of Parkinson’s disease. This project involves a diverse team of researchers from Penn’s Genomics Institute: molecular biologist Dr. James Eberwine; computational scientist Dr. Junhyong Kim; imaging experts Dr. Philip Haydon and Dr. Jai-Yoon Sul; robotics expert Dr. Vijay Kumar; and biological modeling expert Dr. David Meaney.

“The scientific scope of such an interdisciplinary effort has traditionally been difficult to fund through standard NIH mechanisms,” noted Dr. Eberwine, the project’s principal investigator. “The foresight of the Keck Foundation in facilitating this and such efforts at other universities will undoubtedly contribute to the development of scientific innovation and therefore the improvement of the human condition.”

Dr. Eberwine and colleagues will develop new approaches that target the multi-genic nature of Parkinson’s disease. Parkinson’s is a debilitating, progressive neurodegenerative disorder of the central nervous system in which dopamine-producing nerve cells die in those areas of the brain that coordinate voluntary movement and aspects of cognition. The Keck grant will fund the cataloguing of the changes in gene expression that underlie the development of Parkinson’s in individual live neurons and will utilize a newly developed technology for assessing genomic changes in live cells. The goal is to use this information to create neurons that reliably produce dopamine, under natural gene regulation within the cell. Eventually, such cells may prove to be useful in cellular therapeutics.

Current treatments for Parkinson’s using transplanted cells are limited by the traditional one-gene-at-a-time approach to manipulating dopamine production. The new integrated approach, developed by the team, will identify the complex genetic nature of the disease and will be used in efforts to correct the multifaceted gene expression anomalies that underlie Parkinson’s pathology.

More generally, most human diseases and syndromes manifest themselves through the dysregulation of multiple genes. The approaches being developed as part of this Keck grant will permit multiple genes to be manipulated in a predictable, naturally controlled manner. “These studies will provide the first truly functional genomics approach to understanding human disease and eventually, it is hoped, may provide novel therapeutic intervention strategies,” said Dr. Eberwine.

 The W.M. Keck Foundation, established in 1954 by William Myron Keck, founder of The Superior Oil Company, is one of the nation’s largest philanthropic organizations with assets of more than $1 billion. In recent years, the Foundation has focused on five broad areas: Science and Engineering Research; Undergraduate Science and Engineering; Medical Research; Liberal Arts; and Southern California.

Almanac - February 13, 2007, Volume 53, No. 22